256 related articles for article (PubMed ID: 18566380)
1. Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses.
Gerner MY; Casey KA; Mescher MF
J Immunol; 2008 Jul; 181(1):155-64. PubMed ID: 18566380
[TBL] [Abstract][Full Text] [Related]
2. Induction of MHC class I presentation of exogenous antigen by dendritic cells is controlled by CD4+ T cells engaging class II molecules in cholesterol-rich domains.
Machy P; Serre K; Baillet M; Leserman L
J Immunol; 2002 Feb; 168(3):1172-80. PubMed ID: 11801652
[TBL] [Abstract][Full Text] [Related]
3. Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells.
Pooley JL; Heath WR; Shortman K
J Immunol; 2001 May; 166(9):5327-30. PubMed ID: 11313367
[TBL] [Abstract][Full Text] [Related]
4. Anatomic location defines antigen presentation by dendritic cells to T cells in response to intravenous soluble antigens.
Chung Y; Chang JH; Kim BS; Lee JM; Kim HY; Kang CY
Eur J Immunol; 2007 Jun; 37(6):1453-62. PubMed ID: 17474148
[TBL] [Abstract][Full Text] [Related]
5. CD103- and CD103+ bronchial lymph node dendritic cells are specialized in presenting and cross-presenting innocuous antigen to CD4+ and CD8+ T cells.
del Rio ML; Rodriguez-Barbosa JI; Kremmer E; Förster R
J Immunol; 2007 Jun; 178(11):6861-6. PubMed ID: 17513734
[TBL] [Abstract][Full Text] [Related]
6. Antigen processing and MHC-II presentation by dermal and tumor-infiltrating dendritic cells.
Gerner MY; Mescher MF
J Immunol; 2009 Mar; 182(5):2726-37. PubMed ID: 19234167
[TBL] [Abstract][Full Text] [Related]
7. Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.
Ye Z; Ahmed KA; Hao S; Zhang X; Xie Y; Munegowda MA; Meng Q; Chibbar R; Xiang J
Autoimmunity; 2008 Nov; 41(7):501-11. PubMed ID: 18855194
[TBL] [Abstract][Full Text] [Related]
8. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
Tanaka Y; Koido S; Ohana M; Liu C; Gong J
J Immunol; 2005 Feb; 174(3):1274-80. PubMed ID: 15661883
[TBL] [Abstract][Full Text] [Related]
9. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
Homma S; Komita H; Sagawa Y; Ohno T; Toda G
Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
[TBL] [Abstract][Full Text] [Related]
10. NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo.
Stober D; Jomantaite I; Schirmbeck R; Reimann J
J Immunol; 2003 Mar; 170(5):2540-8. PubMed ID: 12594280
[TBL] [Abstract][Full Text] [Related]
11. Increasing the survival of dendritic cells in vivo does not replace the requirement for CD4+ T cell help during primary CD8+ T cell responses.
Matthews KE; Qin JS; Yang J; Hermans IF; Palmowski MJ; Cerundolo V; Ronchese F
J Immunol; 2007 Nov; 179(9):5738-47. PubMed ID: 17947646
[TBL] [Abstract][Full Text] [Related]
12. Whole protein and defined CD8(+) and CD4(+) peptides linked to penetratin targets both MHC class I and II antigen presentation pathways.
Pouniotis DS; Esparon S; Apostolopoulos V; Pietersz GA
Immunol Cell Biol; 2011 Nov; 89(8):904-13. PubMed ID: 21383765
[TBL] [Abstract][Full Text] [Related]
13. Type I interferon supports primary CD8+ T-cell responses to peptide-pulsed dendritic cells in the absence of CD4+ T-cell help.
Ontiveros F; Wilson EB; Livingstone AM
Immunology; 2011 Apr; 132(4):549-58. PubMed ID: 21255009
[TBL] [Abstract][Full Text] [Related]
14. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
[TBL] [Abstract][Full Text] [Related]
15. DC-induced CD8(+) T-cell response is inhibited by MHC class II-dependent DX5(+)CD4(+) Treg.
Han WG; Schuurhuis DH; Fu N; Camps M; van Duivenvoorde LM; Louis-Plence P; Franken KL; Huizinga TW; Melief CJ; Toes RE; Ossendorp F
Eur J Immunol; 2009 Jul; 39(7):1765-73. PubMed ID: 19544486
[TBL] [Abstract][Full Text] [Related]
16. cDC1 prime and are licensed by CD4
Ferris ST; Durai V; Wu R; Theisen DJ; Ward JP; Bern MD; Davidson JT; Bagadia P; Liu T; Briseño CG; Li L; Gillanders WE; Wu GF; Yokoyama WM; Murphy TL; Schreiber RD; Murphy KM
Nature; 2020 Aug; 584(7822):624-629. PubMed ID: 32788723
[TBL] [Abstract][Full Text] [Related]
17. Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity.
Mitsui H; Inozume T; Kitamura R; Shibagaki N; Shimada S
J Invest Dermatol; 2006 Aug; 126(8):1804-12. PubMed ID: 16645583
[TBL] [Abstract][Full Text] [Related]
18. Cognate memory CD4+ T cells generated with dendritic cell priming influence the expansion, trafficking, and differentiation of secondary CD8+ T cells and enhance tumor control.
Hwang ML; Lukens JR; Bullock TN
J Immunol; 2007 Nov; 179(9):5829-38. PubMed ID: 17947656
[TBL] [Abstract][Full Text] [Related]
19. CD4 T cell help is required for primary CD8 T cell responses to vesicular antigen delivered to dendritic cells in vivo.
Serre K; Giraudo L; Siret C; Leserman L; Machy P
Eur J Immunol; 2006 Jun; 36(6):1386-97. PubMed ID: 16673447
[TBL] [Abstract][Full Text] [Related]
20. Carbohydrate-mediated targeting of antigen to dendritic cells leads to enhanced presentation of antigen to T cells.
Adams EW; Ratner DM; Seeberger PH; Hacohen N
Chembiochem; 2008 Jan; 9(2):294-303. PubMed ID: 18186095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
